AR113963A1 - Composiciones y métodos para el tratamiento o la prevención de los síntomas vasomotores - Google Patents

Composiciones y métodos para el tratamiento o la prevención de los síntomas vasomotores

Info

Publication number
AR113963A1
AR113963A1 ARP180103696A ARP180103696A AR113963A1 AR 113963 A1 AR113963 A1 AR 113963A1 AR P180103696 A ARP180103696 A AR P180103696A AR P180103696 A ARP180103696 A AR P180103696A AR 113963 A1 AR113963 A1 AR 113963A1
Authority
AR
Argentina
Prior art keywords
prevention
compositions
treatment
methods
vasomotor symptoms
Prior art date
Application number
ARP180103696A
Other languages
English (en)
Spanish (es)
Inventor
Joseph M Palumbo
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of AR113963A1 publication Critical patent/AR113963A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP180103696A 2017-12-19 2018-12-18 Composiciones y métodos para el tratamiento o la prevención de los síntomas vasomotores AR113963A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762607666P 2017-12-19 2017-12-19

Publications (1)

Publication Number Publication Date
AR113963A1 true AR113963A1 (es) 2020-07-01

Family

ID=65023968

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103696A AR113963A1 (es) 2017-12-19 2018-12-18 Composiciones y métodos para el tratamiento o la prevención de los síntomas vasomotores

Country Status (16)

Country Link
US (2) US11471452B2 (de)
EP (2) EP4059500A1 (de)
JP (2) JP7265551B2 (de)
KR (1) KR20200100746A (de)
CN (1) CN111465395A (de)
AR (1) AR113963A1 (de)
AU (1) AU2018391882A1 (de)
BR (1) BR112020012111A2 (de)
CA (1) CA3085292A1 (de)
CO (1) CO2020007091A2 (de)
IL (1) IL275258A (de)
MX (1) MX2020006468A (de)
PH (1) PH12020550932A1 (de)
SG (1) SG11202005383RA (de)
TW (1) TW201929855A (de)
WO (1) WO2019124366A1 (de)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987445B2 (en) 2011-03-16 2015-03-24 Mitsubishi Tanabe Pharma Corporation Sulfonamide compounds having TRPM8 antagonistic activity
CN103906733A (zh) * 2011-06-24 2014-07-02 安姆根有限公司 Trpm8拮抗剂及其在治疗中的用途
WO2014042238A1 (ja) 2012-09-14 2014-03-20 田辺三菱製薬株式会社 スルホンアミド化合物
JP5985453B2 (ja) 2012-09-14 2016-09-06 田辺三菱製薬株式会社 医薬組成物
AU2013403622B2 (en) 2013-10-22 2019-05-16 Edward Tak Wei Di-isopropyl-phosphinoyl-alkane (DAPA) compounds as topical agents for the treatment of sensory discomfort
CN113398124A (zh) * 2016-06-13 2021-09-17 田边三菱制药株式会社 用于治疗或预防血管舒缩症状的组合物

Also Published As

Publication number Publication date
AU2018391882A2 (en) 2022-06-23
US20220401434A1 (en) 2022-12-22
TW201929855A (zh) 2019-08-01
JP7265551B2 (ja) 2023-04-26
EP4059500A1 (de) 2022-09-21
KR20200100746A (ko) 2020-08-26
CO2020007091A2 (es) 2020-06-19
BR112020012111A2 (pt) 2020-11-24
EP3727383A1 (de) 2020-10-28
JP2021506881A (ja) 2021-02-22
RU2020123723A (ru) 2022-01-20
PH12020550932A1 (en) 2021-05-10
CA3085292A1 (en) 2019-06-27
CN111465395A (zh) 2020-07-28
WO2019124366A1 (en) 2019-06-27
US11471452B2 (en) 2022-10-18
IL275258A (en) 2020-07-30
US20200383968A1 (en) 2020-12-10
AU2018391882A1 (en) 2020-07-02
MX2020006468A (es) 2021-01-08
SG11202005383RA (en) 2020-07-29
JP2023089175A (ja) 2023-06-27

Similar Documents

Publication Publication Date Title
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
CO2017012381A2 (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
DOP2018000196A (es) Metodos para tratar la depresion con antagonistas del receptor de orexina-2
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CR20140086A (es) Tratamientos de combinación para hepatitis c
CL2013002737A1 (es) Acido 4-((4-((((1r, 2s)-2-fenilciclopropil)amino)metil)piperidin-1-il)metil)benzoico con actividad inhibidora de desmetilasa 1 especifica de lisina (lsd1); composicion farmaceutica que lo comprende, utiles en el tratamiento del cancer.
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
CR20190447A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
BR112015029401A2 (pt) derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
AR104068A1 (es) Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
UY36123A (es) Derivados de carboxamida
BR112016017985A2 (pt) Composição farmacêutica para administração tópica e usos da mesma na fabricação de medicamentos
PE20151607A1 (es) Formulaciones de compuestos organicos
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
CL2019003463A1 (es) Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas.
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington